HC Wainwright Expects Reduced Earnings for LENZ Therapeutics

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Analysts at HC Wainwright decreased their Q1 2026 earnings estimates for shares of LENZ Therapeutics in a research note issued on Tuesday, April 21st. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($1.11) per share for the quarter, down from their previous forecast of ($0.86). HC Wainwright currently has a “Buy” rating and a $48.00 price target on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($3.66) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q2 2026 earnings at ($1.06) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.83) EPS, FY2026 earnings at ($3.89) EPS, FY2027 earnings at ($2.72) EPS, FY2028 earnings at ($0.88) EPS, FY2029 earnings at $0.61 EPS and FY2030 earnings at $2.38 EPS.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Tuesday, March 24th. The company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.25). The company had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $3.09 million.

Other research analysts have also issued research reports about the stock. William Blair restated an “outperform” rating on shares of LENZ Therapeutics in a research note on Tuesday, March 10th. Weiss Ratings lowered shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Citigroup cut their price target on shares of LENZ Therapeutics from $52.00 to $26.00 and set a “buy” rating on the stock in a research note on Thursday, March 26th. Bank of America cut their price target on shares of LENZ Therapeutics from $35.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, March 25th. Finally, Wall Street Zen lowered shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $44.00.

LENZ Therapeutics Stock Up 1.2%

NASDAQ LENZ opened at $9.99 on Thursday. The firm has a market cap of $313.19 million, a PE ratio of -3.56 and a beta of 0.66. The company has a 50 day moving average price of $11.07 and a 200 day moving average price of $19.76. LENZ Therapeutics has a 52 week low of $8.25 and a 52 week high of $50.40.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Quarry LP acquired a new stake in shares of LENZ Therapeutics in the third quarter worth $27,000. Bfsg LLC acquired a new stake in shares of LENZ Therapeutics in the third quarter worth $30,000. Osaic Holdings Inc. increased its stake in shares of LENZ Therapeutics by 2,146.2% in the second quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock worth $34,000 after acquiring an additional 1,116 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of LENZ Therapeutics by 51.4% in the second quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock worth $41,000 after acquiring an additional 477 shares during the period. Finally, SBI Securities Co. Ltd. increased its stake in shares of LENZ Therapeutics by 9,235.3% in the third quarter. SBI Securities Co. Ltd. now owns 1,587 shares of the company’s stock worth $74,000 after acquiring an additional 1,570 shares during the period. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.